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SObjective: Invasive mediastinal biopsy is often necessary in the evaluation of non–small cell lung cancer
(NSCLC), and mediastinoscopy has long been considered the reference standard. However, the emergence of
endobronchial ultrasound–guided transbronchial needle aspiration (EBUS-TBNA) has resulted in controversy
regarding it represents a suitable replacement for mediastinoscopy. We chose to determine the utility of
EBUS-TBNA in evaluating the mediastinum in patients with NSCLC.
Methods: The present study was a retrospective review of a prospective database of consecutive patients with
NSCLC who underwent EBUS-TBNA for mediastinal evaluation from 2009 to 2011. The sensitivity, speci-
ficity, negative predictive value, and accuracy of EBUS-TBNA are reported. Also reported are the size of the
lymph nodes biopsied and the number of instances in which EBUS-TBNA obviated the need for cervical
mediastinoscopy.
Results: A total of 73 patients had a total of 140 mediastinal stations biopsied using EBUS-TBNA. Of the 73
patients, 30 had benign findings and underwent surgical resection, 1 of whom was found to have stage N2 dis-
ease. Of the remaining patients, 42 had a positive result and 1 had nondiagnostic biopsy findings for which ma-
lignancy was confirmed by mediastinoscopy. Mediastinoscopy would have changed the tumor stage and
treatment planning in only 2 (2.7%) of the 73 patients. Overall, EBUS-TBNA had a sensitivity of 95%, a spec-
ificity of 100%, a negative predictive value of 94%, and an accuracy of 97%.
Conclusions: EBUS-TBNA might be a feasible option for most patients with NSCLC for whom histologic as-
sessment of the mediastinum is necessary. The rates of nondiagnostic and false-negative biopsy findings using
EBUS-TBNAwere low, small subcentimeter nodes could be routinely biopsied, and most patients with a radio-
graphically positive mediastinum had their disease pathologically confirmed. (J Thorac Cardiovasc Surg
2012;143:585-90)Non–small cell lung cancer (NSCLC) frequently metasta-
sizes to the mediastinal lymph nodes, representing a process
that affects the tumors stage and treatment strategy. Cervical
mediastinoscopy with biopsies has been the reference
standard for staging the mediastinum of patients with
NSCLC for decades.1 However, the use of endobronchial ul-
trasound–guided transbronchial needle aspiration (EBUS-
TBNA) is gaining popularity among physicians involved in
the staging of lung cancer. As a result of this new technology,
a debate has arisen regarding the accuracy of EBUS-TBNA
in correctly determining the presence of mediastinal nodal
disease and the effect of EBUS-TBNA on the need to per-
form cervical mediastinoscopy in this patient population.e Daniel and Gloria Blumenthal Cancer Center,a Paramus, NJ; and Division of
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The Journal of Thoracic and CaSome investigators have found EBUS-TBNA to provide an
accurate examination of the mediastinum. However, others
have maintained that cervical mediastinoscopy should re-
main the definitive biopsy procedure, citing a high false-
negative rate associated with EBUS-guided biopsies.2-5
Given this controversy, we sought to determine the role of
EBUS-TBNA in evaluating the mediastinum in our patients
with NSCLC. Specifically, the purpose of the present study
was to determine the (1) efficacy of EBUS-TBNA, (2) how
often EBUS-TBNA yields a positive result in patients with
a radiographically positive mediastinum, and (3) the non-
diagnostic biopsy rate.METHODS
Study Design and Patient Cohort
The present study was a retrospective review of a prospectively main-
tained database of patients undergoing EBUS-TBNA. The institutional re-
view board waived the need for informed consent. Since September 2009,
all patients who met the standard criteria for cervical mediastinoscopy be-
cause of proven or suspected lung cancer instead underwent EBUS-TBNA.
Generally, this group of patients included those requiring mediastinal stag-
ing before definitive resection (stage IB to IIIA) and those with radio-
graphic stage IIIB disease (large and/or confluent contralateral nodal
mass) or stage IV disease (brain metastasis) who required a tissue
diagnosis.rdiovascular Surgery c Volume 143, Number 3 585
Abbreviations and Acronyms
CT ¼ computed tomography
EBUS-
TBNA
¼ endobronchial ultrasound–guided
transbronchial needle aspiration
L ¼ level
LL ¼ left level
NSCLC ¼ non–small cell lung cancer
PET ¼ positron emission tomography
RL ¼ right level
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radiographically positive, defined as positive findings on computed to-
mography (CT) and/or positron emission tomography (PET). Positive
CT findings meant that lymph nodes in right level (RL) 2, RL4, level 7
(L7), and/or left level (LL) 4 stations had a short axis diameter of greater
than 1 cm. The PET findings were interpreted by institutional radiologists
as positive or negative, comparing the lymph node to the uptake in the
mediastinal blood pool. If positive, the maximum standardized uptake
value was reported.
Patients with radiographically positive mediastinal lymph nodes outside
the paratracheal and subcarinal areas (L5, L6, L8, L9) were excluded from
the present study because these regions are outside the reach of cervical
mediastinoscopy. These patients underwent staging using other modalities,
including thoracoscopy and/or endoesophageal ultrasonography.
EBUS-Guided Mediastinal Biopsies
All EBUS-TBNA procedures were performed with the patient under
general anesthesia through a laryngeal mask airway using an EBUS-
TBNA bronchoscope (Olympus Exera BF-UC180F; Olympus Imaging
America, Center Valley, Pa). Lymph node biopsies were performed using
either a 21- or 22-gauge EBUS-TBNA biopsy needle, from highest to low-
est stage (eg, N3 to N2 to N1). The lymph node size, in and of itself, was not
a determinate of whether biopsy was attempted. Efforts were made to bi-
opsy all nodal basins in all patients undergoing preoperative staging, unless
no obvious nodal tissue was detected in a given station using EBUS. Pa-
tients with intraoperatively confirmed stage IIIB disease did not undergo
multistation biopsies, because therapy would not be affected by the acqui-
sition of more tissue.
Once the biopsy needle was introduced into a candidate lymph node and
suction applied, multiple needle passes (>25) were made, with manipula-
tion of the bronchoscope to ensure thorough nodal sampling. The speci-
mens were placed in cytolyte, and, although rapid on-site evaluation of
slides was available, it was not routinely performed. The decision regarding
repeat biopsy of the same lymph node was determined by gross inspection
of the biopsy specimens in the cytolyte. A biopsy was considered diagnos-
tic if it either contained tumor (‘‘positive’’ EBUS) or benign lymph node
tissue (‘‘negative’’ EBUS; lymphocytes and/or histiocytes). Complications
from the EBUS-guided biopsy procedure were recorded.
Confirmation of EBUS-TBNA Results
The EBUS-TBNA results were confirmed in selected patients by the ad-
ditional acquisition of tissue:
Patients with negative preoperative staging EBUS-TBNA findings
underwent surgical resection using either a thoracoscopic
(video-assisted thoracic surgery) or an open thoracotomy ap-
proach. During all right-sided resections, RL4 and L7, L10, and
L11 were dissected; on the left side, L5, L6, L7, L10, and L11
were dissected.586 The Journal of Thoracic and Cardiovascular SurgPatients with a radiographically positive mediastinum and nondiagnos-
tic EBUS-TBNA findings underwent cervical mediastinoscopy, in
which attempts were made to biopsy RL2, RL4, LL4, and L7 nodal
stations.
Patients with a radiographically positive mediastinum and negative
EBUS-TBNAfindings underwent either resection (as above) or cer-
vical mediastinoscopy (as above), followed by surgical resection, if
negative. The decision to go directly to resection in these cases was
on a case-by-case basis.
Patients with positive EBUS-TBNAfindings, with stage IIIA and an ad-
equate cardiopulmonary reserve underwent preoperative chemo-
therapy followed by surgical resection using an open thoracotomy
approach (as above), when appropriate.
Of note, the patients with positive mediastinal biopsy findings whowere
not surgical candidates because of an advanced disease stage (IIIB) or un-
resectable disease did not undergo additional tissue acquisition from the
mediastinum.
Clinical Stage
The clinical stage was derived from the findings from all noninvasive
and invasive procedures performed before surgical resection, when appro-
priate. The 7th edition of the American Joint Committee on Cancer TNM
staging system for NSCLC was used.
Statistical Analysis
The median and interquartile range were determined for lymph node
size and maximum standard uptake value as determined from the CT and
PET scans, respectively. These quantities were tabulated according to the
result of the EBUS-TBNA procedure. The sensitivity, specificity, negative
predictive value, and accuracy of EBUS-TBNAwere calculated according
to the biopsy results of the lymph nodes that had undergone both
EBUS-TBNA and surgical confirmation. The 95% confidence intervals
for these values are presented.6 Sensitivity was calculated as the number
of true-positive results/(number of true-positive results þ number of
false-negative results). Specificity was calculated as the number of true-
negative results/(number of false-positive results þ number of true-
negative results). The negative predictive value was calculated as the
number of true-negative results/(number of false-negative resultsþnumber
of true-negative results). Accuracy was calculated as the number of
EBUS-TBNA results confirmed by surgical resection/total number of
EBUS-TBNA procedures performed. It was assumed that any lymph
node deemed malignant by EBUS-TBNAwas truly malignant.
RESULTS
Patient Characteristics
From September 2009 to April 2011, 73 patients met the
criteria for inclusion in the present study. The clinical char-
acteristics of the study cohort are listed in Table 1. Of the 73
patients, 57 (78%) had a radiographically positive medias-
tinum using either the CT criteria alone (n ¼ 26), PET cri-
teria alone (n ¼ 1), or combined positive PET and CT
findings (n ¼ 30). Twelve patients had undergone no PET
before EBUS-TBNA. The median maximum standardized
uptake value in the patients with positive PET findings
was 8.8 (interquartile range, 5.28–13), and the median
nodal size (short axis) of the patients with positive CT find-
ings was 2 cm (interquartile range, 1.5–2.6). In the 30 pa-
tients with presumed early-stage disease (stage 1-2), 77
lymph node stations were sampled (2.6 stations/patient).ery c March 2012
TABLE 1. Clinical features (n ¼ 73)
Characteristic Patients (n)
Gender
Male 34 (47)
Female 39 (53)
Age (y)
Mean 69.2
Range 36–91
Primary tumor location
RUL 20 (27)
RML 2 (3)
RLL 15 (21)
LUL 19 (26)
LLL 12 (16)
None 5 (7)
Clinical stage
IA 10 (14)
IB 10 (14)
IIA 3 (4)
IIB 3 (4)
IIIA 20 (27)
T1–T3N2 17
T3N1 2
T4N0 1
IIIB 12 (16)
T1–T3N3 10
T4N2 2
IVA 3 (4)
IVB 12 (16)
Histologic finding
Adenocarcinoma 48 (66)
Squamous 18 (25)
Large cell 3 (4)
Carcinosarcoma 2 (3)
Adenosquamous 1 (1.4)
Carcinoid 1 (1.4)
Data presented as number of patients, with percentages in parentheses. RUL, Right
upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe;
LLL, left lower lobe.
FIGURE 1. Distribution of lymph node sizes biopsied using endobron-
chial ultrasound–guided transbronchial needle aspiration.
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SClinical Outcome and Replacement of Cervical
Mediastinoscopy With EBUS-TBNA
A flow diagram demonstrating the clinical outcome of
all 73 patients in the present study, according to the radio-
graphic status of the mediastinum, is shown in Figure 1.
Significantly, 42 (74%) of the 57 patients with a radio-
graphically positive mediastinum had malignant disease
in the mediastinal lymph nodes proven using EBUS-
TBNA. In the entire cohort, only 4 patients underwent cer-
vical mediastinoscopy after EBUS-TBNA. In 3 of these
patients, the EBUS-TBNA findings were negative despite
a radiographically positive mediastinum. In all 3, the me-
diastinal lymph nodes were negative after both cervical
mediastinoscopy and subsequent video-assisted thoracic
surgery lobectomy. The fourth patient underwent cervical
mediastinoscopy after non-diagnostic EBUS-TBNA forThe Journal of Thoracic and Caa radiographically positive mediastinum, yielding a positive
result (RL4).
Overall, cervical mediastinoscopy was not performed in
69 (95%) of the 73 patients, who, before EBUS-TBNA,
would have undergone the more invasive procedure. Fur-
thermore, only 1 patient had positive mediastinoscopy
findings in the present study, with a single additional pa-
tient undergoing resection with N2 disease discovered,
despite negative EBUS-TBNA findings (no preresection
mediastinoscopy performed). Therefore, cervical mediasti-
noscopy would have changed the tumor stage and treat-
ment planning in only 2 (2.7%) of 73 patients. The
overall sensitivity, specificity, positive predictive value,
negative predictive value, and accuracy for EBUS-TBNA
was 95% (42/44), 100% (29/29), 100% (42/42), 94%
(29/31), and 97% (71/73), respectively. Only 1 complica-
tion (atrial fibrillation) occurred after EBUS-TBNA
(1.4%).
Ability of EBUS-TBNA to Detect Mediastinal Nodal
Disease
In the 73 patients, 140 lymph node stations were biopsied
using EBUS-TBNA. The distribution of lymph node sizes
biopsied using EBUS-TBNA is shown in Figure 2. Of the
EBUS-TBNA biopsies were positive in 51 and negative in
88, with a single nondiagnostic biopsy (RL4). No lymph no-
des were biopsied in RL2. The EBUS-guided biopsy results,
radiographic characteristics, sensitivity, specificity, nega-
tive predictive value, and accuracy according to nodal sta-
tion are listed in Table 2. Only positive biopsy and
negative biopsy findings confirmed by either mediastino-
scopy or at surgical resection were included in the present
analysis (100/140).
DISCUSSION
The utility of EBUS-TBNA in staging the mediastinum in
patients with NSCLC remains controversial (Table 3).4,7-10
Recent data and published reviews have suggested that
many radiographically suspicious nodal stations are eitherrdiovascular Surgery c Volume 143, Number 3 587
FIGURE 2. Endobronchial ultrasound–guided transbronchial needle aspiration (EBUS-TBNA) and patient outcomes. VATS, Video-assisted thoracic
surgery.
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are nondiagnostic.3-5 In addition, many experts have
recommended that, because of the significant false-negative
results obtained with EBUS-TBNA, negative EBUS-TBNATABLE 2. Characteristics of EBUS-guided lymph node biopsies stratified
Station
(node no.)
EBUS-FNA
result (n) CT size* (mm)
MaxSUV
Median (IQR) TP, FN, F
4R (41) 24, 1, 0
Positive 24 24 (17–37.6) 8 (4.5–13)
Negative 16 7 (5–15) 0 (0–0)
ND 1 16 (NA) 5.2 (NA)
4L (6) 4, 0, 0,
Positive 4 36.6 (NA) 12 (NA)
Negative 2 5 (NA) 0 (NA)
ND 0 0 0
7 (53) 23, 1, 0
Positive 23 21.5 (16.5–28.3) 8.9 (5.2–12.1)
Negative 30 9 (7–12.6) 0 (0–0)
ND 0 0 0
Only EBUS-TBNA biopsies subsequently confirmed by either mediastinoscopy or surgica
needle aspiration;CT, computed tomography;MaxSUV,maximum standardized uptake valu
negative result; NPV, negative predictive value; ND, nondiagnostic NA, not able to be calc
parentheses are 95% confidence intervals.
588 The Journal of Thoracic and Cardiovascular Surgfindings need to be confirmed by cervical mediastino-
scopy.1-5,11 The data from the present study contradicts
some of these concerns regarding EBUS-TBNA. The data
suggest that EBUS-TBNA is safe and accurate in detectingby nodal station (n ¼ 100)
P, TN Sensitivityy Specificityy NPVy Accuracyy
, 16 96 (78–100) 100 (76–100) 94 (69–100) 98 (86–100)
2 100 (40–100) 100 (20–100) 100 (20–100) 100 (52–100)
, 29 96 (77–100) 100 (85–100) 97 (81–100) 98 (89–100)
l resection included. EBUS-TBNA, Endobronchial ultrasound–guided transbronchial
e; TP, true-positive result; FN, false-negative result; FP, false-positive result; TN, true-
ulated. *Data presented as median, with interquartile range in parentheses. yData in
ery c March 2012
TABLE 3. Recent publications of EBUS-TBNA for NSCLC
Investigator Year
Patients
(n)
Sensitivity
(%)
NPV
(%)
Accuracy
(%)
Cerfolio et al4 2010 72 57 79 83
Yasufuku et al7 2011 153 84.3 92.7 94.8
Andrade et al8 2010 98 87.9 84.4 91.7
Hwango et al9 2010 150 84.4 93.3 95.1
Szlubowki et al10 2009 226 89 83.5 92.9
EBUS-TBNA, Endobronchial ultrasound–guided transbronchial needle aspiration;
NSCLC, non–small cell lung cancer; NPV, negative predictive value.
Lee et al General Thoracic Surgery
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Smediastinal nodal disease, with both a low nondiagnostic bi-
opsy rate and a low false-negative rate. In addition, diagnostic
tissue can be successfully obtained from small (subcentime-
ter) lymph nodes. Finally, the performance of EBUS-guided
mediastinal node biopsiesmight obviate the need for cervical
mediastinoscopy inmost patientswithNSCLC requiringme-
diastinal assessment.
Maximizing Effect of EBUS-TBNA in Mediastinum
The results from the present study have demonstrated that
EBUS-TBNA is effective in evaluating the mediastinum
and that negative findings might not have to be followed
by cervical mediastinoscopy. In particular, all the patients
with a radiographically negative mediastinum and negative
EBUS-TBNA findings were node negative on final patho-
logic staging. Furthermore, only 1 of 14 patients with
a radiographically positive mediastinum and negative
EBUS-TBNA findings had disease in the mediastinum on
resection. Although this conclusion is in direct contrast to
those from other published reports, several recent studies,
as well as a recently reported prospective clinical trial that
mandated routine cervical mediastinoscopy after every
EBUS-TBNA,7-9 support our conclusion.
We propose that several factors might have played a role
in optimizing the performance of EBUS-guided biopsies in
the present experience. First, general anesthesia was used in
all patients. It is conceivable that the absence of spontane-
ous respiration might have been beneficial, especially
when performing biopsies of small (subcentimeter) lymph
nodes. Second, a larger bore (21-gauge) biopsy needle
was used for most biopsies, regardless of nodal size, which
theoretically could have increased the volume of specimen
acquired. Third, all EBUS-TBNA procedures were per-
formed by the thoracic surgeons who ultimately diagnosed,
staged, and resected all patients. This continuity of care for
these complicated patients might have allowed for a more
thorough staging evaluation with EBUS-TBNA. As an ex-
ample, perhaps the persistence of the EBUS-TBNA opera-
tor to obtain adequate biopsies was affected by this
continuity of care, especially when managing small nodes
in difficult locations. Clearly, these subtle differences in
technique need to be investigated further and directly com-
pared with their counterparts (ie, sedation vs generald Caanesthesia, 21- vs 22-gauge needle) to determine whether
a true benefit exists.
Ability of EBUS-TBNA to Replace Cervical
Mediastinoscopy
Because the experience from the present study did not di-
rectly compare EBUS-TBNA and cervical mediastino-
scopy, we cannot conclude that EBUS-TBNA represents
a suitable replacement for mediastinoscopy. However, in
comparisons such as this, it is important to realize that cer-
vical mediastinoscopy is also associated with a false-
negative rate and is therefore not truly a reference standard.
Yasufuku and colleagues,7 in a rigorously conducted pro-
spective trial, found that cervical mediastinoscopy
‘‘missed’’ nearly as many malignant nodes as did EBUS-
TBNA. They concluded that EBUS-TBNA might be able
to replace cervical mediastinoscopy.7
The accuracy of EBUS-TBNA in evaluating the medias-
tinum of patients with NSCLC will probably never be iden-
tical in every operator’s hands. Just as has been shown with
other ultrasound-based technologies, the accuracy with
EBUS-TBNA is most likely extremely user dependent.12
Inherent operator factors, such as the knowledge of medias-
tinal anatomy and spatial relationships and the aggressive-
ness in performing biopsies, play a role in every
procedure and are difficult to control from institution to in-
stitution and from operator to operator. Perhaps each oper-
ator/institution will need to assess their strengths and
weaknesses with regard to EBUS-TBNA and cervical me-
diastinoscopy and only then derive their own staging
algorithm.
Strengths and Limitations
The strengths of the present analysis included the pro-
spective nature of the data collection and the inclusion of
only those nodal stations accessible using cervical mediasti-
noscopy. Thus, we chose not to complicate the study by in-
cluding the evaluation of L5-L6 nodes because we believe
these levels are not truly accessible using either EBUS-
TBNA or cervical mediastinoscopy. Another strength was
the uniformity of the operators and infrastructure in the
EBUS-TBNA program, with all procedures performed us-
ing the same techniques by only 2 operators.
The main limitation of the present study was that most
EBUS-TBNA procedures were not followed by routine
mediastinoscopy. For example, patients with positive bi-
opsy results by EBUS-TBNA were assumed to have true
disease and did not undergo confirmatory mediastino-
scopy. Accordingly this might introduce the possibility
of workup bias in the present study. Obviously, the most
relevant method to determine whether EBUS-TBNA could
replace mediastinoscopy would be a study in which every
patient underwent both EBUS-TBNA and mediastino-
scopy. However, such a strategy would require a formalrdiovascular Surgery c Volume 143, Number 3 589
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understanding that in many circumstances they would
undergo an ‘‘unnecessary’’ procedure. Given our experi-
ence, combined with the recent published results of a clin-
ical trial that considered this very question, such a trial
would likely need to be performed as a multi-
institutional study.
Another limitation inherent in any study assessing medi-
astinal biopsy techniques is that all the mediastinal nodes
will not be thoroughly dissected in every patient. Even
with open thoracotomy and radical node dissection, specific
nodal basins will not be dissected (eg, the paratracheal no-
des during left-sided pulmonary resection). This is a limita-
tion that is difficult to overcome given the standards of
clinical care for patients with lung cancer.
The relatively small sample sizewas another limitation of
the present study. Ideally, a multi-institutional randomized
study focusing on mediastinal staging in patients with oper-
able NSCLC would provide the best evidence in determin-
ing whether EBUS-TBNA is a suitable replacement for
cervical mediastinoscopy.
In conclusion, our experience with EBUS-TBNA of the
mediastinal lymph nodes for the evaluation of the mediasti-
num in patients with NSCLC suggests that this new technol-
ogy is safe and accurate. The rates of nondiagnostic and
false-negative biopsies were low, small subcentimeter no-
des could be routinely biopsied, and most patients with a ra-
diographically positive mediastinum had their disease
pathologically confirmed by EBUS-TBNA.590 The Journal of Thoracic and Cardiovascular SurgReferences
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